Retinal biologics market value surpassed US$ 14.6 billion in 2018 and projected to grow at 10.7% y-o-y in 2019, as per a new FMI study. The projected growth of the market can be attributed to,Increasing prevalence of diabetic eye diseases and age-related macular degeneration (AMD)Significant R&D investments engaged.
Retinal Biologics Market Expected to Grow With a CAGR of 7 3% During the Forecast Period 2021-2026 briefingwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from briefingwire.com Daily Mail and Mail on Sunday newspapers.
The Retinal Biologics Market report through its overview section
provides the overall scenario and dynamics of the global Retinal Biologics Market with its definition and other details. Further, the key player and competitive landscape segment of the report enlist the various players actively participating and competing in the global market. The report also entails the new market entrants. The key major market players include
Janssen Biotech, Alimera Sciences, F. Hoffmann-La Roche, Ocular Therapeutix, Genzyme Corporation, UCBCares, AbbVie, Allergan, Swedish Orphan Biovitrum, Genentech, Bristol-Myers Squibb, and Bausch & Lomb. The report encompasses the leading manufacturers along with their respective share in the global market in terms of revenue. Moreover, it mentions their tactical steps in the last few years, leadership changes, and product innovation investments to help in making well-informed decisions and also to stay at the forefront in the competition.